Genomic tools in acute myeloid leukemia: From the bench to the bedside

Authors

  • Brian S. White PhD,

    1. Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri
    2. The Genome Institute, Washington University, St. Louis, Missouri
    Search for more papers by this author
  • John F. DiPersio MD, PhD

    Corresponding author
    1. Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri
    2. Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, Missouri
    • Corresponding author: John F. DiPersio, MD, PhD, Division of Oncology, Campus Box 8007, Washington University Medical School, 660 South Euclid Avenue, St. Louis, MO 63110; Fax: (314) 454-7551; jdipersi@dom.wustl.edu

    Search for more papers by this author

  • We thank Joshua McMichael for assistance with figure design and Nicole Maher for critical review of the manuscript.

Abstract

Since its use in the initial characterization of an acute myeloid leukemia (AML) genome, next-generation sequencing (NGS) has continued to molecularly refine the disease. Here, the authors review the spectrum of NGS applications that have subsequently delineated the prognostic significance and biologic consequences of these mutations. Furthermore, the role of this technology in providing a high-resolution glimpse of AML clonal heterogeneity, which may inform future choice of targeted therapy, is discussed. Although obstacles remain in applying these techniques clinically, they have already had an impact on patient care. Cancer 2014;120:1134–1144. © 2014 American Cancer Society.

Ancillary